The Amazing Son-in-Law: Chapters 1651-1655

Chapter 1651

Aurouss Hill Airport. Cameron Isaac’s plane waited in the hangar. Don Albertt and Ichiro Kobayashi were already there, waiting with Liam and Paul for Charlie Wade’s arrival.

At nine in the morning, Cameron Isaac’s motorcade arrived. He personally opened the car door for Charlie Wade. Everyone greeted Charlie Wade upon his exit.

Charlie Wade nodded and asked, “Is everyone here? If so, let’s board the plane.”

Cameron Isaac confirmed, “Mr. Wade, everyone is present.”

“Good, let’s go!”

Besides Cameron Isaac, Don Albertt, Liam, Paul, and Ichiro Kobayashi, twelve additional people from Don Albertt and Cameron Isaac’s teams accompanied Charlie Wade. After boarding, the crew started the engines, taxied, and received takeoff clearance. The plane flew east.

During the flight, Ichiro Kobayashi, visibly nervous, approached Charlie Wade and asked respectfully, “Mr. Wade, what if my family refuses to accept me, believing I murdered my father and preventing my inheritance of Kobayashi Pharmaceutical?”

Charlie Wade replied calmly, “I have a video of Jiro Kobayashi’s confession. I’ll show it to them.”

Ichiro Kobayashi pressed, “What if they still don’t believe it?”

Charlie Wade scoffed, “Don’t believe it? Let’s go through the legal process. They claim you murdered your father; can they provide tangible evidence? If not, what can they do?”

Charlie Wade continued, “Besides, your brother has disappeared. You’re the sole heir. Those who oppose you will be removed from Kobayashi Pharmaceutical.”

Ichiro Kobayashi, slightly emboldened, said, “Mr. Wade, my uncles and family elders, though lacking shares, hold influential positions on the board of directors. If they oppose me, it won’t be easy…”

Charlie Wade responded indifferently, “Not a problem. We’ll offer them two choices: cooperate honestly and retain their dividends, or face removal and the restructuring of the management team. If necessary, I’ll deploy a management team from Oracle Pharmaceuticals, and you can enjoy a leisurely life in Japan.”

Ichiro Kobayashi understood that after transferring 90% of the shares to Charlie Wade, his involvement with Kobayashi Pharmaceutical would be minimal. He would receive dividends and live comfortably.

Chapter 1652

Reflecting, Ichiro Kobayashi felt guilty, believing he was selling his father’s legacy. While not a prodigal son, he wasn’t aiming for mere extravagance. His goal was to revitalize Kobayashi Pharmaceutical, not simply acquire Dr. Simmons’s formula. He sought to elevate the company globally, for the sake of his family. Now, he risked ruining it.

Yet, he also saw a potential benefit. Oracle Nova Dias’s success suggested enormous future profits. Kobayashi Pharmaceutical, under Charlie Wade, could become incredibly profitable. His 10% stake could yield significant returns. This eased his worry.

Over two hours later, Charlie Wade’s plane landed at Tokyo Airport. Cameron Isaac’s men, driving a fleet of Rolls-Royces, waited. This was unusual in Japan, where local brands dominate.

Cameron Isaac opened a Rolls-Royce door for Charlie Wade and asked, “Master, where to first?”

Charlie Wade directed, “Kobayashi Pharmaceutical headquarters.”

Cameron Isaac cautioned, “Master, the Kobayashi family is complex. Bringing Ichiro Kobayashi might be difficult.”

Charlie Wade smiled, “The more complex, the quicker we resolve it. I’m here to make money, not friends. I won’t painstakingly untangle their family drama.”

Cameron Isaac worried, “Master, Kobayashi Pharmaceutical is a hundred-billion-dollar company. Its members might try to seize control, seeing Ichiro Kobayashi and Jiro as gone.”

Charlie Wade calmly replied, “Legally, no one can stop Ichiro Kobayashi. Those who oppose him will be dealt with.”

Chapter 1653

Kobayashi Pharmaceutical’s Tokyo headquarters was preparing for an emergency shareholder meeting. Jiro Kobayashi’s disappearance in China left the company leaderless. Initially, shareholders searched for him, contacting Ito Takehiko, who had expressed interest in Jiro Kobayashi as a son-in-law and acquiring shares. Jiro's trip to China was to pursue Ito Takehiko’s daughter, Nanako Ito. Nanako returned, but Jiro vanished, baffling the Kobayashis.

Ito Takehiko also investigated, but lacking intelligence networks in China, failed. He eventually gave up the search, focusing instead on installing a new president. The Kobayashi family followed suit.

After abandoning the search for Jiro, the family prepared to restructure Kobayashi Pharmaceutical. While many family members were involved, they lacked direct share ownership. After Masao Kobayashi's death, Ichiro was labeled a murderer, leaving Jiro as the sole heir. Jiro’s disappearance, under Japanese law, could lead to his legal death, allowing collateral relatives to inherit. Masayoshi Kobayashi, Ichiro’s uncle, became acting chairman. Ito Takehiko turned his attention to Masayoshi.

Chapter 1654

Ito Takehiko called Masayoshi Kobayashi, congratulating him on his position. Masayoshi, while happy, maintained he was only a temporary replacement. Ito Takehiko scoffed, predicting Masayoshi would become the permanent chairman.

Ito Takehiko proposed a business deal: acquiring a 30% stake in Kobayashi Pharmaceutical for $15 billion. Masayoshi protested, claiming the company was worth over $20 billion. Ito countered with two additional offers: $200 million in cash and securing Masayoshi's position as chairman if he facilitated the deal at the lower price. This would save Ito millions.

Masayoshi considered the enormous profit difference. He initially hesitated but was tempted by the cash and secured leadership. He proposed a revised deal: $500 million in cash in exchange for ensuring Ito's share acquisition.

Chapter 1655

Kobayashi Pharmaceutical’s meeting room held anxious collateral family members and executives. The old president's death and Jiro’s suspected murder had shaken them. However, Masayoshi’s promise of a 40% profit distribution created anticipation. Masayoshi entered, greeted with reverence as the new god of wealth.

He emphasized his temporary role, hoping for Jiro’s return. He then highlighted Oracle Pharmaceutical's Nova Dias, a potential competitor whose superior medicine threatened Kobayashi Pharmaceutical's Niranex. A member confirmed Nova Dias’s effectiveness through a personal experience. Masayoshi declared Oracle a mortal enemy, warning that if Nova Dias gained market share, Kobayashi Pharmaceutical’s revenue would plummet. The executives were stunned.